19 Jul Astellas Pharma
Richard Wilson, Senior Vice President, Primary Focus Lead (Genetic Regulation), Astellas
Oct. 11 | 4:15pm | Ecolab Life Sciences Ballroom
Tokyo, Japan
(NASDAQ: ALPMY)
At Astellas, we aim to discover, develop and deliver breakthrough gene therapies with life-changing VALUE for patients across many disease areas. We are developing a pipeline of potentially transformative therapies and building an end-to-end gene therapy powerhouse with industry-leading discovery, development, manufacturing and commercial capabilities. We have two candidates in clinical development for rare neuromuscular diseases: AT845, in Phase 1/2 for Pompe disease and AT132 for X-linked myotubular myopathy, currently on clinical hold. We are also working to build our robust portfolio across other indications with significant unmet medical need – including A2016 for Friedreich’s ataxia, in the preclinical phase. Alongside our partners, clinicians, regulatory authorities and patient communities, we strive to overcome complex challenges across all stages of research, development and commercialization. With an ambition to establish ourselves as leaders in gene therapy, we hope to transform the promise of complex, ground-breaking science into a scalable operation for patients.
